A23L33/00

ELECTROSTATIC SPRAY DRIED MILK PRODUCT AND PRODUCTION METHOD THEREOF

Provided is an electrostatic spray dried powdered milk product with a surface composition comprising at least 8% less fat compared to a spray dried powder of the same milk product. Further provided is a method of providing a powdered milk product comprising electrostatic spray drying a milk product at an inlet temperature of below 150° C. The electrostatic spray dried milk product powder has a surface composition with a reduced fat content and increased carbohydrate content relative to the same milk product powder prepared by high heat spray drying.

UTILIZATION OF A FASTING-MIMICKING DIET TO REDUCE SENESCENT CELLS AND INFLAMMATION

A method for reducing senescence-positive cells in a subject includes a step of identify a subject having increased expression of p16INK4a or at risk for increased of p16INK4a. A fasting-mimicking diet is administered to the subject for a first time period.

UTILIZATION OF A FASTING-MIMICKING DIET TO REDUCE SENESCENT CELLS AND INFLAMMATION

A method for reducing senescence-positive cells in a subject includes a step of identify a subject having increased expression of p16INK4a or at risk for increased of p16INK4a. A fasting-mimicking diet is administered to the subject for a first time period.

NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
20230038577 · 2023-02-09 ·

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

MIXTURE OF HMOS FOR IMPROVING THE MICROBIOTA OF PREGNANT WOMEN

The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.

Nutritional intervention for improving muscular function and strength

The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

PHARMACEUTICAL COMPOSITION AND HEALTH FUNCTIONAL FOOD FOR PREVENTING, AMELIORATING OR TREATING THROMBOSIS CONTAINING EXTRACT OF VESPA VELUTINA NIGRITHORAX AS ACTIVE INGREDIENT
20230038188 · 2023-02-09 ·

An antithrombotic composition containing an extract of Vespa velutina nigrithorax as an active ingredient, and more particularly, a pharmaceutical composition and a health functional food for preventing, ameliorating or treating thrombosis by inhibition of blood coagulation and inhibition of platelet aggregation, which contain an ethyl acetate fraction of an extract of Vespa velutina nigrithorax as an active ingredient. The extract exhibits antithrombotic activity by inhibiting platelet aggregation while exhibiting strong anticoagulant activity by inhibiting thrombosis-related enzymes and blood clotting factors. Also, the extract has no human erythrocyte hemolytic activity, has excellent heat stability, and the thrombosis-related enzyme and blood clotting factor inhibitory effects thereof are not lost even under an acidic condition of pH 2 and in plasma.

PROCESS FOR TREATING SWEET WHEY SUCH AS TO OBTAIN A PROTEIN MATERIAL SUITABLE FOR HYPOALLERGENIC INFANT FORMULAE
20180000103 · 2018-01-04 ·

The invention concerns a process for the treatment of a sweet whey material containing cGMP (caseinoGlycoMacroPeptide), said process comprising the following steps: —Decationising the sweet whey material so as to obtain sweet whey material having a pH value of 1 to 4.5; —Treating said sweet whey in a fluidized bed reactor comprising a specific volume of an anionic resin, at a temperature between 10 and 18° C., wherein said sweet whey contacts said resin for a sufficient amount of time so that the resin absorbs between 52% and 58% of the cGMP present in the sweet whey; and—Recovering a protein material. Advantageously, the protein material is suitable for hypoallergenic infant formulae.

EXPANDED DRY PROTEIN-BASED FOOD PRODUCT AND METHOD FOR PRODUCING SAME
20180000117 · 2018-01-04 · ·

The invention relates to an expanded dry food product comprising at least the following ingredients: a food-grade plant- or animal-based protein concentrate; a food-grade fat; a food-grade texturising additive selected from the group consisting of plant-based hydrocolloids and gelling agents, starch, preferably modified starch, proteolytic additives and hydrolysis products thereof, and acidifying agents and salts thereof; and residual water. The invention also relates to a method for producing said expanded dry food product from a thermally expandable precursor.

Phosphatidylserine-Containing Diet Supplement Aids With Melatonin Anti-Catabolic Dietary Nutrients
20180000881 · 2018-01-04 ·

A supplement includes plant-derived phosphatidylserine in a physiologically beneficial amount and at least one plant-based concentrate or extract which promotes a melatonergic benefit.